Effects of carbamazepine on dexamethasone suppression and sleep electroencephalography in borderline personality disorder.
The pathophysiology of borderline personality disorder (BPD) remains obscure, but there is mounting evidence of brain dysfunction without focal abnormality. The dexamethasone suppression test (DST) and sleep electroencephalography (sleep EEG) have been studied in BPD, but the findings seem to be related to a concomitant axis I diagnosis of major depression (MD) rather than to BPD itself. There is no effective treatment for BPD. Carbamazepine (CBZ) has shown contradictory results and in a previous study, our results were negative. In this study, we investigated the effects of CBZ versus placebo on the DST and sleep EEG in a sample of 20 BPD patients without concomitant MD. CBZ given at doses that are therapeutic for epilepsy and affective disorders may have an effect on the DST and sleep EEG in BPD. CBZ significantly increased the postdexamethasone plasma cortisol values. This did not parallel MD or an increase in the Hamilton depression rating scores. CBZ also increased slow wave sleep (SWS). The mechanisms by which CBZ increased postdexamethasone plasma cortisol levels and SWS in BPD are discussed.
De la Fuente
José M
JM
Department of Psychiatry, Erasme Hospital, Free University of Brussels, Brussels, Belgium. jdlf@ch-lannemezan.fr
Bobes
Julio
J
Vizuete
Coro
C
Mendlewicz
Julien
J
D000328:Adult; D001883:Borderline Personality Disorder / Q000188:drug therapy* / Q000503:physiopathology*; D001921:Brain / Q000503:physiopathology; D002220:Carbamazepine / Q000494:pharmacology / Q000627:therapeutic use*; D003907:Dexamethasone; D004569:Electroencephalography / Q000187:drug effects*; D005260:Female; D005938:Glucocorticoids; D006801:Humans; D008297:Male; D011569:Psychiatric Status Rating Scales; D012894:Sleep Stages / Q000187:drug effects*
D005938:Glucocorticoids; D002220:Carbamazepine; D003907:Dexamethasone